drugset / Trial / NCT02303795

RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

NCT02303795

Phase 2 Completed 1005 enrolled Hospital do Coracao
RandomizedParallel-groupOpen-labelTreatment

Summary

RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).

Timeline

Start
2015-08
Primary completion
2020-08
Completion
2020-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rivaroxaban Other / unclassified 15 mg Oral
Comparator Rivaroxaban Other / unclassified 20 mg Oral
Comparator Warfarin Small molecule 2.5 mg Oral
Comparator Warfarin Small molecule 5 mg Oral

Indications